PepSight
WEIGHT MANAGEMENT

Orforglipron

Orforglipron is a weight management peptide used in evidence-based, physician-supervised protocols. First-line oral weight loss when patient refuses injectable GLP-1, or as bridge therapy.

What is Orforglipron?

Non-peptide small-molecule oral GLP-1 receptor agonist. Activates GLP-1R to suppress appetite, slow gastric emptying, increase insulin secretion, and reduce glucagon. Fully oral — bypasses injectable peptide limitations. TITRATION PROTOCOL: 3mg x14 days → 6mg x14 days → 12mg x14 days → 24-45mg maintenance.

Uses & clinical decision logic

First-line oral weight loss when patient refuses injectable GLP-1, or as bridge therapy. Take on empty stomach 30 min before food.

Orforglipron dosage & administration

Vial sizeBAC waterDosing rangeUnits / doseFrequencyRoute
Oral CapN/A (oral)3-45mg1 capsule1x/dayOral

Safety & contraindications

Same class as semaglutide — nausea/vomiting at initiation; titrate carefully. Contraindicated in pancreatitis history, MEN2/MTC.

Stacking & combinations

Do not combine with injectable semaglutide/tirzepatide simultaneously. Can add AOD-9604 or 5-Amino-1MQ for complementary mechanisms.

Related peptides

Frequently asked questions

What is Orforglipron used for?

First-line oral weight loss when patient refuses injectable GLP-1, or as bridge therapy. Take on empty stomach 30 min before food.

What is the typical Orforglipron dosage?

Common dosing ranges from 3-45mg (1x/day, Oral). Exact dosing is individualized and set by a licensed physician.

How is Orforglipron administered?

Orforglipron is typically administered via Oral.

What are the contraindications for Orforglipron?

Same class as semaglutide — nausea/vomiting at initiation; titrate carefully. Contraindicated in pancreatitis history, MEN2/MTC.

Considering Orforglipron?

Build a physician-supervised protocol around your goal — no gatekeeping, real doctors, 503A compounding pharmacies.

Build your protocol →

This page is for educational purposes only and is not medical advice. Peptide therapies described here are provided under physician supervision through 503A compounding pharmacies. Many peptides are not FDA-approved for the uses described. Do not start, stop, or change any protocol without consulting a licensed physician.